Risk stratification by the expressions of 5 m6A-related genes (YTHDF1, HNRNPC, RBM15, METTL3, and YTHDF2) could improve the prognosis prediction of HCC and was related to the response to sorafenib treatment and anti-PD-1 immunotherapy (69, 101, 102). Here, METTL3 is linked to hepatocellular carcinoma.